BAX
BEARISH
$16.91
Live
Baxter International Inc. · NYSE
Target $22.19
(+31.2%)
$15.73
52W Range
$33.83
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 01, 2026
Market cap
$8.73B
P/E
N/A
ROE
-13.7%
Profit margin
-8.5%
Debt/Equity
1.6
Dividend yield
2.14%
AI Analysis
AI-powered fundamental assessment
Confidence
60%
BAX shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Concerns include weak profitability or high valuation.
Key Strengths
Company has established market presence
Key Risks
Low profit margin of -8.5%
Weak financial trend (Piotroski F-Score: 2/9)
Weak ROE of -13.7%
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
36
Weak
50
50
30
30
20
AI Verdict
BAX shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Concerns include weak profitability or high valuation.
Key drivers: Company has established market presence, Low profit margin of -8.5%, Weak financial trend (Piotroski F-Score: 2/9)
Confidence
20%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
50/100
Rule-based growth outlook.
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Past
30/100
Historical performance + price trend: Shares moved -77.7% over 5Y and -49.6% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
- ROE only -13.7%.
- Thin profit margins.
Health
30/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
20/100
Dividend policy fallback.
Positives
- Yield: 2.1%.
Watchpoints
- Weak dividend profile (Score: 20/100).
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$16.91
Analyst Target
$22.19
Upside/Downside
+31.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BAX and closest competitors.
Updated 2026-04-01
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BAX
Baxter International Inc.
Primary
|
-77.7% | -54.7% | -49.6% | -27.5% | -14.1% | -1.2% |
|
HSIC
Henry Schein, Inc.
Peer
|
+7.6% | -11.6% | +18.5% | +19.3% | -1.5% | +1.9% |
|
BTSG
BrightSpring Health Services, Inc.
Peer
|
+298.8% | +298.8% | +153.9% | +54.4% | +3.9% | +3.0% |
|
ICLR
ICON Public Limited Company
Peer
|
-43.0% | -45.5% | -19.8% | -38.0% | +19.4% | +9.3% |
|
CRL
Charles River Laboratories International, Inc.
Peer
|
-49.5% | -9.5% | +46.7% | -13.8% | +2.4% | -7.7% |
BAX
Baxter International Inc.
Primary
5Y
-77.7%
3Y
-54.7%
1Y
-49.6%
6M
-27.5%
1M
-14.1%
1W
-1.2%
HSI
Henry Schein, Inc.
Peer
5Y
+7.6%
3Y
-11.6%
1Y
+18.5%
6M
+19.3%
1M
-1.5%
1W
+1.9%
BTS
BrightSpring Health Services, Inc.
Peer
5Y
+298.8%
3Y
+298.8%
1Y
+153.9%
6M
+54.4%
1M
+3.9%
1W
+3.0%
ICL
ICON Public Limited Company
Peer
5Y
-43.0%
3Y
-45.5%
1Y
-19.8%
6M
-38.0%
1M
+19.4%
1W
+9.3%
CRL
Charles River Laboratories International, Inc.
Peer
5Y
-49.5%
3Y
-9.5%
1Y
+46.7%
6M
-13.8%
1M
+2.4%
1W
-7.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
8.25
PEG Ratio
N/A
P/B Ratio
1.42
P/S Ratio
0.78
EV/Revenue
1.46
EV/EBITDA
8.14
Market Cap
$8.73B
Profitability
Profit margins and return metrics
Profit Margin
-8.51%
Operating Margin
7.36%
Gross Margin
35.73%
ROE
-13.71%
ROA
2.83%
Growth
Revenue and earnings growth rates
Revenue Growth
+8.0%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.6
High debt
Current Ratio
2.31
Strong
Quick Ratio
1.31
Good
Cash/Share
$3.82
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$3.0B
Gross Margin
19.4%
Op. Margin
-8.2%
Net Margin
-37.9%
Total Assets
$20.1B
Liabilities
$14.0B
Equity
$6.1B
Debt/Equity
2.28x
Operating CF
$0.6B
CapEx
$-0.1B
Free Cash Flow
$0.4B
FCF Yield
76%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-12
$0.44
-17.8% surprise
2025-10-30
$0.69
+15.4% surprise
2025-07-31
$0.59
-3.3% surprise
Healthcare Sector Comparison
Comparing BAX against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-13.71%
This Stock
vs
-88.14%
Sector Avg
-84.4%
(Below Avg)
Profit Margin
-8.51%
This Stock
vs
-16.28%
Sector Avg
-47.7%
(Weaker)
Debt to Equity
1.6
This Stock
vs
2.66
Sector Avg
-39.8%
(Less Debt)
Revenue Growth
8.0%
This Stock
vs
124.04%
Sector Avg
-93.6%
(Slower)
Current Ratio
2.31
This Stock
vs
4.47
Sector Avg
-48.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BAX
Baxter International Inc.
|
BEARISH | $8.73B | - | -13.7% | -8.5% | $16.91 | |
|
HSIC
Henry Schein, Inc.
|
BULLISH | $8.65B | 23.04 | 8.7% | 3.0% | $75.34 | Compare |
|
BTSG
BrightSpring Health Services, Inc.
|
NEUTRAL | $8.43B | 91.4 | 5.9% | 1.5% | $43.87 | Compare |
|
ICLR
ICON Public Limited Company
|
NEUTRAL | $9.06B | 15.7 | 6.3% | 7.4% | $116.5 | Compare |
|
CRL
Charles River Laboratories...
|
NEUTRAL | $8.38B | - | -4.2% | -3.6% | $169.8 | Compare |
BAX
Baxter International Inc.
BEARISH
Mkt Cap
$8.7B
P/E
-
ROE
-13.7%
Price
$16.91
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | CARLISLE CYNTHIA | Officer | Stock Award | 29,677 | - |
| 2026-02-27 | SORIANO MARIA CECILIA | Officer | Stock Award | 23,742 | - |
| 2026-02-27 | ZIELINSKI ANITA A. | Officer | Stock Award | 30,864 | - |
| 2026-02-27 | ROSENBLOOM DAVID S | General Counsel | Stock Award | 26,709 | - |
| 2026-02-27 | HIDER ANDREW P | Chief Executive Officer | Stock Award | 201,804 | - |
| 2026-02-27 | GRADE JOEL T. | Chief Financial Officer | Stock Award | 42,735 | - |
| 2026-02-13 | MCDONNELL MICHAEL R | Director | Stock Award | 1,811 | - |
| 2026-02-09 | SORIANO MARIA CECILIA | Officer | Stock Award | 2,273 | - |
| 2026-02-09 | ROSENBLOOM DAVID S | General Counsel | Stock Award | 17,055 | - |
| 2026-02-09 | RASUL REAZ | Officer | Stock Award | 18,951 | - |
| 2026-02-09 | GRADE JOEL T. | Chief Financial Officer | Stock Award | 30,504 | - |
CARLISLE CYNTHIA
Officer
2026-02-27
29,677 shares
SORIANO MARIA CECILIA
Officer
2026-02-27
23,742 shares
ZIELINSKI ANITA A.
Officer
2026-02-27
30,864 shares
ROSENBLOOM DAVID S
General Counsel
2026-02-27
26,709 shares
HIDER ANDREW P
Chief Executive Officer
2026-02-27
201,804 shares
GRADE JOEL T.
Chief Financial Officer
2026-02-27
42,735 shares
MCDONNELL MICHAEL R
Director
2026-02-13
1,811 shares
SORIANO MARIA CECILIA
Officer
2026-02-09
2,273 shares
ROSENBLOOM DAVID S
General Counsel
2026-02-09
17,055 shares
RASUL REAZ
Officer
2026-02-09
18,951 shares
GRADE JOEL T.
Chief Financial Officer
2026-02-09
30,504 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
13 analysts
Citigroup
2026-03-11
Neutral
Neutral
Goldman Sachs
2026-02-17
Neutral
Neutral
Barclays
2026-02-13
Overweight
Overweight
Barclays
2026-01-09
Overweight
Overweight
Morgan Stanley
2025-12-02
Underweight
Underweight
Citigroup
2025-10-31
Neutral
Neutral
Goldman Sachs
2025-10-31
Neutral
Neutral
UBS
2025-10-31
Neutral
Neutral
Argus Research
2025-10-31
Buy
Hold
Evercore ISI Group
2025-10-07
Outperform
Outperform
Past News Coverage
Recent headlines mentioning BAX from our newsroom.
Newest → oldest
No matching news yet.